{"disease":{"id":"refractory-liver-carcinoma","name":"refractory liver carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02940496","title":"Pembrolizumab (MK-3475) in Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03655002","title":"IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}